

2008 Citations to Scientific Publications of the Institute for Neurological Research

1. *Case study of new drug suggests a novel method of targeting Alzheimers symptoms.* Aging Health, 2008. **4**(1): p. 5-9.
2. *Positive effects of etanercept on Alzheimer's disease symptoms.* Expert Review of Neurotherapeutics, 2008. **8**(2): p. 179.
3. *Perispinal administration of anti-TNF agent results in rapid cognitive improvement in AD.* Nature Clinical Practice Neurology, 2008. **4**(4): p. 181.
4. Abdipranoto, A., S. Wu, S. Stayte, and B. Vissel, *The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development.* CNS Neurol Disord Drug Targets, 2008. **7**(2): p. 187-210.
5. Antoniu, S.A., F. Mihaltan, and R. Ulmeanu, *Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases.* Expert Opin Investig Drugs, 2008. **17**(8): p. 1203-11.
6. Balistreri, C.R., M.P. Grimaldi, M. Chiappelli, F. Licastro, L. Castiglia, F. Listi, S. Vasto, D. Lio, C. Caruso, and G. Candore, *Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease.* Curr Pharm Des, 2008. **14**(26): p. 2672-7.
7. Baune, B.T., F. Wiede, A. Braun, J. Golledge, V. Arolt, and H. Koerner, *Cognitive dysfunction in mice deficient for TNF- and its receptors.* Am J Med Genet B Neuropsychiatr Genet, 2008. **147B**(7): p. 1056-64.
8. Berbaum, K., K. Shanmugam, G. Stuchbury, F. Wiede, H. Korner, and G. Munch, *Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array.* Cytokine, 2008. **41**(3): p. 198-203.
9. Brietzke, E. and F. Kapczinski, *TNF-alpha as a molecular target in bipolar disorder.* Prog Neuropsychopharmacol Biol Psychiatry, 2008. **32**(6): p. 1355-61.
10. Buchhave, P., H. Zetterberg, K. Blennow, L. Minthon, S. Janciauskiene, and O. Hansson, *Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment.* Neurobiol Aging, 2008.
11. Burnett, C. and M. Day, *Recent advancements in the treatment of lumbar radicular pain.* Curr Opin Anaesthesiol, 2008. **21**(4): p. 452-6.
12. Constantin, C.E., N. Mair, C.A. Sailer, M. Andratsch, Z.Z. Xu, M.J. Blumer, N. Scherbakov, J.B. Davis, H. Bluethmann, R.R. Ji, and M. Kress, *Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model.* J Neurosci, 2008. **28**(19): p. 5072-81.
13. Etz, C.D., M. Luehr, F.A. Kari, C.A. Bodian, D. Smego, K.A. Plestis, and R.B. Griep, *Paraplegia after extensive thoracic and thoracoabdominal aortic aneurysm repair: does critical spinal cord ischemia occur postoperatively?* J Thorac Cardiovasc Surg, 2008. **135**(2): p. 324-30.
14. Ferguson, A.R., R.N. Christensen, J.C. Gensel, B.A. Miller, F. Sun, E.C. Beattie, J.C. Bresnahan, and M.S. Beattie, *Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane.* J Neurosci, 2008. **28**(44): p. 11391-400.
15. Fietta, P., *The immunosenescence.* Riv Biol, 2008. **101**(2): p. 247-63.
16. Furst, D.E., E.C. Keystone, B. Kirkham, A. Kavanaugh, R. Fleischmann, P. Mease, F.C. Breedveld, J.S. Smolen, J.R. Kalden, G.R. Burmester, J. Braun, P. Emery, K. Winthrop, B. Bresnihan, F. De Benedetti, T. Dorner, A. Gibofsky, M.H. Schiff, J. Sieper, N. Singer, P.L. Van Riel, M.E. Weinblatt, and M.H. Weisman, *Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.* Ann Rheum Dis, 2008. **67 Suppl 3**: p. iii2-25.
17. Goldberg, R.J., *Case reports show etanercept improves AD symptoms - larger trials needed.* Brown University Geriatric Psychopharmacology Update, 2008.

- 12(3): p. 1-8.
18. Goldberg, R.J., *International conference on Alzheimer's disease 2008: Summary of new research: perispinal etanercept improves primary progressive aphasia*. Brown University Geriatric Psychopharmacology Update, 2008. **12**(10): p. 4.
 19. Griffin, W.S., *Perispinal etanercept: potential as an Alzheimer therapeutic*. J Neuroinflammation, 2008. **5**: p. 3.
 20. Hayashi, S., A. Taira, G. Inoue, T. Koshi, T. Ito, M. Yamashita, K. Yamauchi, M. Suzuki, K. Takahashi, and S. Ohtori, *TNF-alpha in nucleus pulposus induces sensory nerve growth: a study of the mechanism of discogenic low back pain using TNF-alpha-deficient mice*. Spine, 2008. **33**(14): p. 1542-6.
 21. Husain, M.M., K. Trevino, H. Siddique, and S.M. McClintock, *Present and prospective clinical therapeutic regimens for Alzheimer's disease*. Neuropsychiatr Dis Treat, 2008. **4**(4): p. 765-77.
 22. Janelsins, M.C., M.A. Mastrangelo, K.M. Park, K.L. Sudol, W.C. Narrow, S. Oddo, F.M. LaFerla, L.M. Callahan, H.J. Federoff, and W.J. Bowers, *Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice*. Am J Pathol, 2008. **173**(6): p. 1768-82.
 23. Jirillo, E., G. Candore, T. Magrone, and C. Caruso, *A scientific approach to anti-ageing therapies: state of the art*. Curr Pharm Des, 2008. **14**(26): p. 2637-42.
 24. Kauer-Sant'anna, M., F. Kapczinski, A.C. Andreazza, D.J. Bond, R.W. Lam, L. Trevor Young, and L.N. Yatham, *Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder*. Int J Neuropsychopharmacol, 2008: p. 1-12.
 25. Kenna, H.A., M.F. Reynolds, B. Jiang, and N. Rasgon, *Insulin resistance link between depressive disorders and Alzheimer's disease, Chapter 4 in Insulin Resistance Syndrome and Neuropsychiatric Disease*. 2008: Informa Health Care.
 26. Maczurek, A., K. Shanmugam, and G. Munch, *Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease*. Ann N Y Acad Sci, 2008. **1126**: p. 147-51.
 27. Marchalant, Y., H.M. Brothers, and G.L. Wenk, *Inflammation and aging: can endocannabinoids help?* Biomed Pharmacother, 2008. **62**(4): p. 212-7.
 28. Marousi, S., J. Ellul, and M. Karakantza, *Genetic polymorphisms of type-1 and type-2 inflammatory cytokines in ischaemic stroke*. Vascular Disease Prevention, 2008. **5**(2): p. 89-103.
 29. McAfoose, J. and B.T. Baune, *Evidence for a cytokine model of cognitive function*. Neurosci Biobehav Rev, 2008.
 30. McAlpine, F.E. and M.G. Tansey, *Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's*. J Inflammation Research, 2008. **1**: p. 29-39.
 31. McCoy, M.K. and M.G. Tansey, *TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease*. J Neuroinflammation, 2008. **5**: p. 45.
 32. Patel, J.R. and G.J. Brewer, *Age-related changes to tumor necrosis factor receptors affect neuron survival in the presence of beta-amyloid*. J Neurosci Res, 2008. **86**(10): p. 2303-13.
 33. Racchi, M., D. Uberti, S. Govoni, M. Memo, C. Lanni, S. Vasto, G. Candore, C. Caruso, L. Romeo, and G. Scapagnini, *Alzheimer's disease: new diagnostic and therapeutic tools*. Immun Ageing, 2008. **5**: p. 7.
 34. Ramanan, S., M. Kooshki, W. Zhao, F.C. Hsu, and M.E. Robbins, *PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways*. Free Radic Biol Med, 2008.
 35. Rao, A.A., K.K. Reddi, and H. Thota, *Bioinformatic analysis of Alzheimer's*

- disease using functional protein sequences. *J Proteomics Bioinformatics*, 2008. **1**(1): p. 47-56.
36. Rogers, J., *The inflammatory response in Alzheimer's disease*. *J Periodontol*, 2008. **79**(8 Suppl): p. 1535-43.
 37. Schwab, C. and P.L. McGeer, *Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders*. *J Alzheimers Dis*, 2008. **13**(4): p. 359-69.
 38. Shamji, M.F., L. Whitlatch, A.H. Friedman, W.J. Richardson, A. Chilkoti, and L.A. Setton, *An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration*. *Spine*, 2008. **33**(7): p. 748-54.
 39. Shin, H.S., T.H. Kim, and S.J. Lee, *The effective steroid dose of caudal epidural injection with unilateral epidural catheter position in patients with symptomatic herniated nucleus pulposus*. *Korean J Anesthesiol*, 2008. **54**(4): p. 427-430.
 40. Steinman, L., *Nuanced roles of cytokines in three major human brain disorders*. *J Clin Invest*, 2008. **118**(11): p. 3557-63.
 41. Tansey, M.G. and T. Wyss-Coray, *Cytokines in CNS Inflammation and Disease, in Central Nervous System Diseases and Inflammation*. 2008: Springer.
 42. Theoharides, T.C. and R. Doyle, *Autism, gut-blood-brain barrier, and mast cells*. *J Clin Psychopharmacol*, 2008. **28**(5): p. 479-83.
 43. Uceyler, N. and C. Sommer, *[Cytokine regulation and pain. Results of experimental and clinical research]*. *Schmerz*, 2008. **22**(6): p. 652-64.
 44. Uceyler, N. and C. Sommer, *Cytokine regulation in animal models of neuropathic pain and in human diseases*. *Neurosci Lett*, 2008. **437**(3): p. 194-8.
 45. van Marum, R.J., *Current and future therapy in Alzheimer's disease*. *Fundam Clin Pharmacol*, 2008. **22**(3): p. 265-74.
 46. Williams, H., *A unifying hypothesis for hydrocephalus, Chiari malformation, syringomyelia, anencephaly and spina bifida*. *Cerebrospinal Fluid Res*, 2008. **5**: p. 7.
 47. Zanella, J.M., E.N. Burright, K. Hildebrand, C. Hobot, M. Cox, L. Christoferson, and W.F. McKay, *Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model*. *Spine*, 2008. **33**(3): p. 227-34.
 48. Teeling, J.L. and V.H. Perry, *Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms*. *Neuroscience*, 2009. **158**(3): p. 1062-73.